季節性インフルエンザワクチン:世界におけるワクチンの実用化機会分析

VacZine Analyticsが発行した調査報告書(DATA6120713)
◆英語タイトル:MarketVIEW: Seasonal influenza vaccines - Global vaccine commercial opportunity assessment
◆商品コード:DATA6120713
◆発行会社(リサーチ会社):VacZine Analytics
◆発行日:2016年6月
◆ページ数:※お問い合わせください。
◆レポート形式:英語 / PDF、Excel
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Executive Presentation (PDF)USD3,800 ⇒換算¥429,400見積依頼/購入/質問フォーム
Forecast Model (Excel)USD3,800 ⇒換算¥429,400見積依頼/購入/質問フォーム
PDF+ExcelUSD7,599 ⇒換算¥858,687見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。VacZine Analytics社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Executive presentation + forecast model(s)

【レポートの目次】

※レポートの目次
http://www.vaczine-analytics.com/VAMV036_TOC_160516.pdf

Author’s notes
Executive summary
[SECTION] Seasonal influenza vaccines: key model outputs
Seasonal influenza vaccine(s): predicted volume to 2034 (GLOBAL)
Seasonal influenza vaccine(s): predicted market to 2030 (GLOBAL)
Seasonal influenza vaccine(s): predicted volume to 2034 (USA)
Seasonal influenza vaccine(s): predicted volume to 2034 (EU5+CAN)
Seasonal influenza vaccine(s): predicted volume to 2034 (EU5+ CAN) by country
Seasonal influenza vaccine(s): predicted volume to 2034 (UK) by target group
Seasonal influenza vaccine(s): predicted volume to 2034 (ROW)
Seasonal influenza vaccine(s): predicted market to 2034 (USA)
Seasonal influenza vaccine(s): predicted market to 2034 (EU5+CAN)
Seasonal influenza vaccine(s): market value per country 2014 (ROW)
USA market: forecast by current product type to 2030
USA market: forecast by competitor 2016-2021
Seasonal influenza vaccine(s): adoption of QIVs - 2015 (doses 000s)
Changes from January 2014 forecast/rationale
Potential val/vol of childhood programs for France, Germany, Italy, Spain to 2030
[SECTION] Seasonal influenza: a review of activity/vaccination recommendations in major markets
US: brief review of 2015-2016 season.
Percentage of Visits for Influenza-like Illness (ILI) US. ILINet
2015-2016 season: Latest synopsis (at Week 13 (ending April 2, 2016)
Vaccine effectiveness: US 2015-2016 influenza season
Vaccine effectiveness: US 2005-2015
US influenza seasons 2000 to 2015/16 - vaccine doses distributed
Seasonal influenza vaccines : vaccine product options US (2015/16)
Seasonal influenza vaccines : vaccine format options US (2013/14)
Flu Vaccination Coverage, United States, 2013-15 Influenza Season
US ACIP recommendations - changes for 2015-2017 seasons
United Kingdom: brief review of influenza season 2015/2016
United Kingdom: influenza vaccine coverage rates (2015/2016)
United Kingdom: elements of Flu Plan 2015-2016
United Kingdom: position on Fluenz Tetra® (LAIV)
United Kingdom: numbers vaccinated 2011/12 vs 2012/13 vs 2014/15
United Kingdom: numbers vaccinated: 2014/15 (2 - 4 yrs)
Major EU countries: influenza intensities, spread and virus/subtype
France: influenza vaccination recommendations 2015/16
Germany: influenza vaccination recommendations 2015/16
Italy: influenza vaccination recommendations 2015/16
Spain: influenza vaccination recommendations 2015/16
Seasonal influenza vaccine usage: EU25 (2012/13 season) – highlights
Seasonal influenza vaccine usage: EU25 (2012/13 season) MAP
Major 5EU countries: vaccine procurement/delivery (000s), 2012/13
Influenza vaccine doses distributed per 1000 population
[SECTION] Seasonal influenza vaccines: Update on competitor activity - 2016
Major influenza vaccine suppliers: global sales 2011 - 2015 ($m)
Major influenza vaccine suppliers: % US sales 2015
US influenza vaccine market per company 2011-2015
US market: competitor production 2000-2015 (doses 000s)
Sanofi Pasteur: key highlights for 2015/2016 season
Sanofi Pasteur – influenza vaccine franchise (US)
Sanofi Pasteur – global influenza vaccine sales (2010 - 2015)
Sanofi Pasteur – US differentiation strategy (2012 - 2015)
Sanofi Pasteur – forecast influenza vaccine US sales (2016 - 2021)
Sanofi Pasteur – is INTANZA successful?
GSK: key highlights for 2015/2016 season
GSK Bio – influenza vaccine franchise (US)
GSK Bio – global influenza vaccine sales (2011 - 2015)
GSK Bio – forecast influenza vaccine US sales (2016 - 2021)
GSK Bio –forecasting QIV UK (public) doses (2016 - 2020)
AZ/MedImmune: key highlights for 2015/2016 season
AZ/MedImmune: key highlights for 2015/2016 season (cont..)
AZ/MedImmune – US influenza vaccine franchise
AZ/MedImmune – global influenza vaccine sales (2011 - 2015)
AZ/MedImmune – forecast influenza vaccine US sales (2016 - 2021)
AZ/Medimmune –forecasting LAIV demand UK (2016 - 2020)
AZ/Medimmune – potential revenues from further childhood programs
Seqirus: key highlights for 2015/2016 season
Seqirus – progress with QIVs
Seqirus – influenza vaccine franchise
Seqirus – 2014 FY results and 2015/2016 HY results
Seqirus – forecast influenza vaccine US sales (2016 - 2021)
Protein Sciences Corporation (3 slides)
Other key marketed seasonal influenza vaccines (global)
[SECTION] Seasonal influenza vaccines: modelling potential demand/commercial value
Countries included in demand forecast model
Populations modelled to 2035
Modelling strategy: segments/countries
Coverage assumptions per country/target group (West)
Coverage assumptions per country/target group (ROW) I – public
Coverage assumptions per country/target group (ROW) II – public
Coverage assumptions per country/target group (ROW) I – private
Coverage assumptions per country/target group (ROW) II – private
Major Western countries: model validations on usage
ROW Countries modelled: summary of schedule/volumes
ROW Countries modelled: summary of schedule/volumes (cont..)
Second dose coverage rates applied
Risk groups
Validating model US volumes - 2014/15
Pricing methodology (TIV, QIV, LAIV, other)
Weighted average pricing methodology
Validating US $ market value – 2015
The impact of price discounting (US)
The impact of price discounting (UK/EU) and QIVs
QIV use outside of US (Australia)
Forecasting QIVs: global market (excl USA) to 2034
Model caveats and limitations
References/bibliography
About VacZine Analytics
Disclaimer
PAGES: ~122 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form


【レポートのキーワード】

季節性インフルエンザワクチン

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 季節性インフルエンザワクチン:世界におけるワクチンの実用化機会分析(MarketVIEW: Seasonal influenza vaccines - Global vaccine commercial opportunity assessment)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆